the Hong Kong College of Cardiology

AL.: Pulmonary Vein Electrical Isolation for the Cure of Paroxysmal Atrial Fibrillation Guided by a Novel Geometry Mapping System. Objectives: The purpose of the study is to evaluate the feasibility and effect of left wall (LA) ablation guided by a novel geometry mapping system in the treatment of older patients with paroxysmal atrial fibrillation (PAF). Methods: Regular electrophysiological study was conducted to exclude atrioventricular reentrant tachycardia (AVRT) with accessory pathways, atrioventricular nodal reentrant tachycardia (AVNRT) and other inducible tachyarrhythmias. Twice transseptal puncture was achieved with L1 and R1 Swartz sheaths. Pulmonary vein (PV) angiographies were conducted to evaluate their orifices and branches. LA geometry was constructed under either sinus rhythm or PAF using Ensite3000 Navx system. Two lesion loops and three lines (see details in the text) for electrical isolation were outlined and created by radiofrequency catheter ablation on the three-dimension geometry of LA. Each lesion point was ablated in 30 seconds with preset temperature 50°C and energy 30W. The disappearance or 80% decrease of the amplitude of LA target potential and 10 to 20 Ω decrease of ablation impedance were used as effective index. Results: Three patients included two males and one female of age 67.3±3.6. PAF history was 7.4±5.1 years. Mean 3.5± 1.2 antiarrhythmic agents were used in 5.7±2.3 years without PAF effectively prevention. No organic heart diseases and stroke complications were founded. Left atrium was 38.7±3.2 mm and LVEF was 58.6±4.3 on echocardiography. Altogether 59-126 (63.7±11.2) lesion points were created to complete two loops and three lines. Rapid burst pacing up to 600 beats per minute was delivered from the distal coronary sinus electrode pair without PAF provoked. The procedure time was 2.8±0.7 hours and fluoroscopy time was 19.6± 8.3 minutes. Patients were discharged with long-term oral warfarin and without any antiarrhythmic agent. During the follow up of 5.6±2.3 months, one patient was free of symptom and PAF attacks were decreased more than 80% in the other two patients by evaluation of Holter monitoring. Conclusions: Ensite3000 Navx guided LA wall ablation near PV orifice to cure PAF in the elderly is safe and feasible and has the advantages of clear procedure endpoint, shorter X-ray exposure, less complication and satisfied long-term effect. Large number of cases and long-term follow up data are needed to validate these primary results. (J HK Coll Cardiol 2004;12: 58-63)

[1]  Ipen,et al.  Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. , 2024, Heart rhythm.

[2]  C. Kumana,et al.  Increased adrenomedullin expression in lungs in endotoxaemia. , 2004, The Journal of endocrinology.

[3]  W. Yin,et al.  Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. , 2004, American heart journal.

[4]  R. Bigi,et al.  Exercise versus recovery electrocardiography in predicting mortality in patients with uncomplicated myocardial infarction. , 2004, European heart journal.

[5]  C. Klein,et al.  Intermedin Is a Calcitonin/Calcitonin Gene-related Peptide Family Peptide Acting through the Calcitonin Receptor-like Receptor/Receptor Activity-modifying Protein Receptor Complexes* , 2004, Journal of Biological Chemistry.

[6]  P. Elwood,et al.  QT dispersion, QT maximum and risk of cardiac death in the Caerphilly Heart Study , 2004, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[7]  H. Mori,et al.  Effects of Adrenomedullin Inhalation on Hemodynamics and Exercise Capacity in Patients With Idiopathic Pulmonary Arterial Hypertension , 2004, Circulation.

[8]  C. May,et al.  Direct coronary vasodilator action of adrenomedullin is mediated by nitric oxide , 2003, British journal of pharmacology.

[9]  K. Kitamura,et al.  Plasma adrenomedullin is closely correlated with pulse wave velocity in middle-aged and elderly patients. , 2003, Hypertension research : official journal of the Japanese Society of Hypertension.

[10]  N. Kobayashi,et al.  Chronic Administration of Adrenomedullin Attenuates Transition From Left Ventricular Hypertrophy to Heart Failure in Rats , 2003, Hypertension.

[11]  J. Cockcroft,et al.  Haemodynamic effects of adrenomedullin in human resistance and capacitance vessels. , 2003, British journal of clinical pharmacology.

[12]  Y. Suematsu,et al.  Accelerated cardiac hypertrophy and renal damage induced by angiotensin II in adrenomedullin knockout mice. , 2003, Hypertension research : official journal of the Japanese Society of Hypertension.

[13]  E. Stabile,et al.  Is Pulmonary Vein Isolation Necessary for Curing Atrial Fibrillation? , 2003, Circulation.

[14]  Nader Rifai,et al.  Preanalytic and analytic sources of variations in C-reactive protein measurement: implications for cardiovascular disease risk assessment. , 2003, Clinical chemistry.

[15]  Ottavio Alfieri,et al.  Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. , 2003, Journal of the American College of Cardiology.

[16]  K. Ellenbogen,et al.  Ablation of atrial fibrillation: awaiting the new paradigm. , 2003, Journal of the American College of Cardiology.

[17]  F. Cuttitta,et al.  Adrenomedullin and cancer , 2003, Regulatory Peptides.

[18]  L. Chao,et al.  Adrenomedullin gene delivery inhibits neointima formation in rat artery after balloon angioplasty , 2003, Regulatory Peptides.

[19]  Chuncai Xue,et al.  Clinical significance of serum cardiac troponin T in patients with congestive heart failure. , 2003, Chinese medical journal.

[20]  H. Nishimatsu,et al.  Endothelial responses of the aorta from adrenomedullin transgenic mice and knockout mice. , 2003, Hypertension research : official journal of the Japanese Society of Hypertension.

[21]  J. Senges,et al.  Catheter Ablation of Chronic Atrial Fibrillation with Noncontact Mapping: , 2003, Pacing and clinical electrophysiology : PACE.

[22]  U. Ikeda,et al.  Adrenomedullin expression in coronary circulation after stent implantation as a prognostic factor for restenosis , 2003, International journal of cardiovascular interventions.

[23]  Y. Asada,et al.  Beneficial effects of adrenomedullin on left ventricular remodeling after myocardial infarction in rats. , 2002, Cardiovascular research.

[24]  F. Spinale,et al.  Effects of Adrenomedullin on Human Myocyte Contractile Function and β-Adrenergic Response , 2002, Journal of cardiovascular pharmacology and therapeutics.

[25]  I. Chaudry,et al.  Novel Approach to Prevent the Transition From the Hyperdynamic Phase to the Hypodynamic Phase of Sepsis: Role of Adrenomedullin and Adrenomedullin Binding Protein-1 , 2002, Annals of surgery.

[26]  Hakan Oral,et al.  Clinical significance of early recurrences of atrial fibrillation after pulmonary vein isolation. , 2002, Journal of the American College of Cardiology.

[27]  J. Alonso-Martínez,et al.  C‐reactive protein as a predictor of improvement and readmission in heart failure , 2002, European journal of heart failure.

[28]  J. Duarte,et al.  Role of endothelium-derived relaxing factors in adrenomedullin-induced vasodilation in the rat kidney. , 2002, European journal of pharmacology.

[29]  T. Eto A review of the biological properties and clinical implications of adrenomedullin and proadrenomedullin N-terminal 20 peptide (PAMP), hypotensive and vasodilating peptides , 2001, Peptides.

[30]  E Geraci,et al.  Assessment of absolute risk of death after myocardial infarction by use of multiple-risk-factor assessment equations: GISSI-Prevenzione mortality risk chart. , 2001, European heart journal.

[31]  C. Lau,et al.  Increase in plasma adrenomedullin in patients with heart failure characterised by diastolic dysfunction , 2001, Heart.

[32]  U Ravens,et al.  Task Force on Sudden Cardiac Death of the European Society of Cardiology. , 2001, European heart journal.

[33]  M. Cleman,et al.  Serum complement activation in congestive heart failure. , 2001, American heart journal.

[34]  C. Rask-Madsen,et al.  Prognostic value of exercise testing in a cohort of patients followed for 15 years after acute myocardial infarction. , 2001, European heart journal.

[35]  A. Richards,et al.  Hemodynamic, Hormone, and Urinary Effects of Adrenomedullin Infusion in Essential Hypertension , 2000, Hypertension.

[36]  D. Strachan,et al.  C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. , 2000, European heart journal.

[37]  J. Danesh,et al.  Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses , 2000, BMJ : British Medical Journal.

[38]  R. Nagai,et al.  Hypotension and resistance to lipopolysaccharide-induced shock in transgenic mice overexpressing adrenomedullin in their vasculature. , 2000, Circulation.

[39]  J. Gardin,et al.  Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. , 2000, Journal of the American College of Cardiology.

[40]  A. Richards,et al.  Hemodynamic, hormonal, and renal effects of short-term adrenomedullin infusion in healthy volunteers. , 2000, The Journal of clinical endocrinology and metabolism.

[41]  M. Leinonen,et al.  Infections, inflammation, and the risk of coronary heart disease. , 2000, Circulation.

[42]  M. Santacana,et al.  Distribution of adrenomedullin-like immunoreactivity in the rat central nervous system by light and electron microscopy , 2000, Brain Research.

[43]  S. Anker,et al.  The role of inflammatory mediators in chronic heart failure: cytokines, nitric oxide, and endothelin-1. , 2000, International journal of cardiology.

[44]  Jayne S. Truckenbrod,et al.  Congestive Heart Failure , 2000, Springer New York.

[45]  K. Kataoka,et al.  Serial circulating concentrations of c‐reactive protein, interleukin (il)‐4, and il‐6 in patients with acute left heart decompensation , 1999, Clinical cardiology.

[46]  C. Tai,et al.  Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins: electrophysiological characteristics, pharmacological responses, and effects of radiofrequency ablation. , 1999, Circulation.

[47]  R. Nagai,et al.  C-Reactive Protein in Dilated Cardiomyopathy , 1999, Cardiology.

[48]  H. Kishida,et al.  Clinical significance of elevated levels of cardiac troponin T in patients with chronic heart failure. , 1999, The American journal of cardiology.

[49]  D. Mann Mechanisms and models in heart failure: A combinatorial approach. , 1999, Circulation.

[50]  P. Wang,et al.  Reduction in vascular responsiveness to adrenomedullin during sepsis. , 1999, The Journal of surgical research.

[51]  J. Mair,et al.  A novel biochemical approach to congestive heart failure: cardiac troponin T. , 1999, American heart journal.

[52]  H. Cohen,et al.  Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. , 1999, The American journal of medicine.

[53]  I. Kushner,et al.  Acute-phase proteins and other systemic responses to inflammation. , 1999, The New England journal of medicine.

[54]  A. Döring,et al.  C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. , 1999, Circulation.

[55]  N. Minamino,et al.  Increased Plasma Concentration of Adrenomedullin in Patients with Subarachnoid Hemorrhage , 1998, Anesthesia and analgesia.

[56]  S. Garrigue,et al.  Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. , 1998, The New England journal of medicine.

[57]  E. Erdmann,et al.  Significance of exercise-induced ST-segment elevation and T-wave pseudonormalization for improvement of function in healed Q-wave myocardial infarction. , 1998, The American journal of cardiology.

[58]  Melanie G. Lee,et al.  RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor , 1998, Nature.

[59]  J. Potratz,et al.  Relation between QT dispersion and the extent of myocardial ischemia in patients with three-vessel coronary artery disease. , 1998, The American journal of cardiology.

[60]  Samsonov,et al.  The activated immune system and the renin–angiotensin–aldosterone system in congestive heart failure , 1998, Journal of internal medicine.

[61]  A. Harada,et al.  Prognostic value of second generation cardiac troponin T in patients with chronic heart failure , 1998 .

[62]  K. Werdan The activated immune system in congestive heart failure – from dropsy to the cytokine paradigm , 1998, Journal of internal medicine.

[63]  R. Bonow,et al.  Chronic heart failure in the United States: a manifestation of coronary artery disease. , 1998, Circulation.

[64]  R. Bigi,et al.  Prognostic value of residual ischaemia assessed by exercise electrocardiography and dobutamine stress echocardiography in low-risk patients following acute myocardial infarction. , 1997, European heart journal.

[65]  T. Fujita,et al.  Plasma adrenomedullin in diabetes , 1997, The Lancet.

[66]  B. Krämer,et al.  Adrenomedullin stimulates renin release and renin mRNA in mouse juxtaglomerular granular cells. , 1997, Hypertension.

[67]  G. MacGowan,et al.  Circulating interleukin-6 in severe heart failure. , 1997, The American journal of cardiology.

[68]  J. Burnett,et al.  Role of prostaglandins and renal nerves in the renal actions of adrenomedullin. , 1997, The American journal of physiology.

[69]  D. Nicholls,et al.  Cytokine profile in chronic cardiac failure , 1996, European journal of clinical investigation.

[70]  B. Bozkurt,et al.  Basic mechanisms in heart failure: the cytokine hypothesis. , 1996, Journal of cardiac failure.

[71]  K. Kitamura,et al.  Inhibition of aldosterone production by adrenomedullin, a hypotensive peptide, in the rat. , 1996, Hypertension.

[72]  Y. Hirata,et al.  Increased circulating adrenomedullin, a novel vasodilatory peptide, in sepsis. , 1996, The Journal of clinical endocrinology and metabolism.

[73]  Y. Koiwaya,et al.  Increased plasma adrenomedullin in acute myocardial infarction. , 1996, American heart journal.

[74]  H. Ruskoaho,et al.  Inotropic effect of adrenomedullin in the isolated perfused rat heart. , 1996, Acta physiologica Scandinavica.

[75]  J. Yoshikawa,et al.  Adrenomedullin as a novel antiproliferative factor of vascular smooth muscle cells , 1996, Journal of hypertension.

[76]  N. Aiyar,et al.  Discovery of adrenomedullin in rat ischemic cortex and evidence for its role in exacerbating focal brain ischemic damage. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[77]  C. May,et al.  ACTH‐Suppressive and Vasodilator Actions of Adrenomedullin in Conscious Sheep , 1995, Journal of neuroendocrinology.

[78]  O. Febo,et al.  Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. , 1995, Circulation.

[79]  N. Minamino,et al.  Effects of vasoactive substances and cAMP related compounds on adrenomedullin production in cultured vascular smooth muscle cells , 1995, FEBS letters.

[80]  J. Burnett,et al.  Elevation of circulating and ventricular adrenomedullin in human congestive heart failure. , 1995, Circulation.

[81]  Shokei Kim,et al.  Attenuation of adrenomedullin‐induced renal vasodilatation by NG‐nitro L‐arginine but not glibenclamide , 1995, British journal of pharmacology.

[82]  D. Smith,et al.  An abundant and specific binding site for the novel vasodilator adrenomedullin in the rat. , 1995, Endocrinology.

[83]  N. Minamino,et al.  Interleukin-1, tumor necrosis factor and lipopolysaccharide additively stimulate production of adrenomedullin in vascular smooth muscle cells. , 1995, Biochemical and biophysical research communications.

[84]  T. Ishimitsu,et al.  Plasma levels of adrenomedullin, a newly identified hypotensive peptide, in patients with hypertension and renal failure. , 1994, The Journal of clinical investigation.

[85]  K. Kangawa,et al.  Distribution and characterization of immunoreactive rat adrenomedullin in tissue and plasma , 1994, FEBS letters.

[86]  Shokei Kim,et al.  Effect of adrenomedullin on renal hemodynamics and functions in dogs. , 1994, European journal of pharmacology.

[87]  T. Ishimitsu,et al.  Genomic structure of human adrenomedullin gene. , 1994, Biochemical and biophysical research communications.

[88]  K. Kangawa,et al.  Hemodynamic effects of a novel hypotensive peptide, human adrenomedullin, in rats. , 1993, European journal of pharmacology.

[89]  K. Kangawa,et al.  Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. , 1993, Biochemical and biophysical research communications.

[90]  S. Cobbe,et al.  Study of serum C-reactive protein concentration in cardiac failure. , 1990, British heart journal.

[91]  S. Silver,et al.  Heart Failure , 1937, The New England journal of medicine.

[92]  W. Samson Adrenomedullin and the control of fluid and electrolyte homeostasis. , 1999, Annual review of physiology.

[93]  Y. Yazaki,et al.  Upregulation of endothelin-1 and adrenomedullin gene expression in the mouse endotoxin shock model. , 1998, Journal of cardiovascular pharmacology.

[94]  S. Bloom,et al.  Circulating adrenomedullin does not regulate systemic blood pressure but increases plasma prolactin after intravenous infusion in humans: a pharmacokinetic study. , 1997, The Journal of clinical endocrinology and metabolism.

[95]  B. Cheung,et al.  Elevated plasma levels of human adrenomedullin in cardiovascular, respiratory, hepatic and renal disorders. , 1997, Clinical science.

[96]  Guidelines for the diagnosis of heart failure. The Task Force on Heart Failure of the European Society of Cardiology. , 1995, European heart journal.